Chronic Uncontrolled Gout

Clinical trial pipeline · Data from ClinicalTrials.gov

See which Chronic Uncontrolled Gout trials you may qualify for

Total trials

Actively recruiting

Phase 3 trials

Completed

Trial phase breakdown

Trial status

Actively recruiting — 1 trial

RecruitingPhase 2

NCT07116746

Evaluation of Efficacy and Safety of AR882 and XOI Co-administration in Uricase Treatment Failed Patients

This study will assess the effect of AR882 and XOI co-administration on sUA lowering as well as reducing tophus burden in the population that has failed uricase…

United States25 participantsStarted 2025-12-03

Treatment: AR882 75 mg, XOI Low Dose

All recent trials (4 shown)

CompletedPhase 4

NCT06229145

A Trial to Investigate the Non-inferiority of Pegloticase Administered Every 4 Weeks (Q4W) With MTX Compared With Every…

The study consists of 24-week double-blind trial to evaluate the non-inferiority of the efficacy and safety of pegloticase Q4W with MTX versus pegloticase Q2W w…

United States262 participantsStarted 2024-03-18

Treatment: Pegloticase, Methotrexate

CompletedPhase 4

NCT04511702

Infusion Duration Study To Assess Tolerability of Pegloticase Administered With a Shorter Infusion Duration in Subjects…

The purpose of this study is to assess the safety, tolerability and efficiency of pegloticase administered with a shorter infusion duration in participants with…

United States191 participantsStarted 2020-10-02

Treatment: Pegloticase with MTX

Chronic Uncontrolled Gout

Trial phase breakdown

Trial status

Actively recruiting — 1 trial

Evaluation of Efficacy and Safety of AR882 and XOI Co-administration in Uricase Treatment Failed Patients

All recent trials (4 shown)

A Trial to Investigate the Non-inferiority of Pegloticase Administered Every 4 Weeks (Q4W) With MTX Compared With Every…

Infusion Duration Study To Assess Tolerability of Pegloticase Administered With a Shorter Infusion Duration in Subjects…

Trial phase breakdown

Trial status

Actively recruiting — 1 trial

Evaluation of Efficacy and Safety of AR882 and XOI Co-administration in Uricase Treatment Failed Patients

All recent trials (4 shown)

A Trial to Investigate the Non-inferiority of Pegloticase Administered Every 4 Weeks (Q4W) With MTX Compared With Every…

Infusion Duration Study To Assess Tolerability of Pegloticase Administered With a Shorter Infusion Duration in Subjects…

A Phase 4, Open-label Study of KRYSTEXXA® (Pegloticase) Co-administered With Methotrexate (MTX) in Patients With Uncontr…